# Use of Ozone-Depleting Substances; Removal of Essential Use Designations
> **Food and Drug Administration** · Direct final rule. · Published 2006-12-07 · Effective 2007-04-23 · 71 FR 70870
## Document
- **Document number:** E6-20797
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 71 FR 70870
- **CFR reference:** 21 CFR 2
- **Publication date:** 2006-12-07
- **Effective date:** 2007-04-23
- **HHS docket:** Docket No. 2006N-0416
## Abstract

The Food and Drug Administration (FDA) is amending its regulation on the use of ozone-depleting substances (ODSs) in pressurized containers to remove the essential use designations for beclomethasone, dexamethasone, fluticasone, bitolterol, salmeterol, ergotamine tartrate, and ipratropium bromide used in oral pressurized metered-dose inhalers (MDIs). Under the Clean Air Act, FDA, in consultation with the Environmental Protection Agency (EPA), is required to determine whether an FDA-regulated product that releases an ODS is essential. None of these products is currently being marketed, which provides grounds for removing their essential use designation. We are using direct final rulemaking for this action because the agency expects that there will be no significant adverse comment on the rule. In the proposed rule section in this issue of the Federal Register, we are concurrently proposing and soliciting comments on this rule. If significant adverse comments are received, we will withdraw this final rule and address the comments in a subsequent final rule. FDA will not provide additional opportunity for comment.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2006/12/07/E6-20797/use-of-ozone-depleting-substances-removal-of-essential-use-designations)
---
*AI Analytics · CC0 1.0*